Median Technologies awarded phase II clinical trial on NSLC

Median Technologies has been awarded a phase II clinical trial on non-small lung cancer

Median Technologies has been awarded a phase II clinical trial on non-small lung cancer (NSLC), with the clinical sites set to be located in Japan, Korea, China and Taiwan.
Between 85 to 95 per cent of lung cancers are the non-small variety, which can require treatments including surgery, chemotherapy and radiotherapy.
As a medical imaging solutions developer, Median will be responsible for organising the independent central reviews of the images for this study - which is being sponsored by Oxford Oncology.
Chief executive of Median Fredrik Brag explained the group now has a number of ongoing studies across Asia and has a growing installed base of imaging centres using its Lesion Management Solutions software for these trials.
"This is an exciting study and we look forward to developing a long-term partnership with Oxford Oncology," Mr Brag said.
According to a statement from Median, the total project award is around 417,000 euros.